AACR 2024 | Phase I dose expansion results of CYT-0851 plus capecitabine in platinum-resistant ovarian cancer

Elizabeth Swisher, MD, University of Washington in Seattle, WA, discusses the Phase I (NCT03997968) dose expansion results of CYT-0851, a monocarboxylate transporter (MCT) inhibitor, in combination with capecitabine in platinum-resistant ovarian cancer. The study yielded exciting findings with a promising response rate in heavily treated patients. Prof. Swisher highlights the potential of this combination therapy in addressing the needs of platinum-resistant ovarian cancer patients. This interview took place at the American Association for Cancer Research (AACR) Annual Meeting 2024 in San Diego, CA.

These works are owned by Magdalen Medical Publishing (MMP) and are protected by copyright laws and treaties around the world. All rights are reserved.